The average cost basis for U.S. spot Bitcoin ETF holders is estimated at $81,722, marking the price level where the average ETF position would return to a loss. Bitcoin recently rose above this level for the first time since January, signaling a break-even point for many holders. U.S. spot Bitcoin ETFs saw net inflows totaling $31 million on Sept. 28, with strong inflows from BlackRock and Grayscale funds. The market will watch ETF flows and Bitcoin's price action around $81,722 closely after key U.S. economic data releases on Sept. 30 to gauge investor sentiment and potential price direction.
Bitcoin ETF holders face an estimated loss threshold at $81,722, marking the average cost basis for U.S. spot Bitcoin ETFs. For readers following cryptocurrency markets, 17 out of 50 major cryptocurrencies on Pluang rose today while 32 fell. Notable movers include CRV at Rp6.972 with a 3.52% decline and a typical hold time of 62 days, as of Sep 30, 2026 14:51 WIB.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
